Clinical Management of Diabetic Macular Edema

Joseph M. Coney, MD, and Theodore Leng, MD, FACS, define diabetic macular edema and explain the typical symptoms to watch for and patient referral patterns.

Retina specialists describe how diabetic retinopathy leads to diabetic macular edema, and the pathophysiology of the condition.

Dr Theodore Leng reviews the preferred testing options for diabetic macular edema.

A panel of experts explains how diabetic macular edema progresses over time and how to educate patients about progression prevention.

A professor of ophthalmology describes how concomitant conditions with diabetic macular edema affect the urgency of treatment regimens.

Ehsan Rahimy, MD, and Joseph M. Coney, MD, review the available treatment options for diabetic macular edema.

Theodore Leng, MD, FACS, describes the currently available anti-VEGF agents for treating diabetic macular edema and what factors to consider when choosing a therapy.

Retina experts discuss the limitations of anti-VEGF agents in treating diabetic macular edema.

Dr Joseph M. Coney reviews his personal experience using anti-VEGF agents to treat diabetic macular edema in his clinical practice.

Ehsan Rahimy, MD, and Theodore Leng, MD, FACS, discuss how to assess patient response to treatment and when to switch agents.

Key opinion leaders describe maintenance treatments for diabetic macular edema and provide an overview of the PANORAMA study.

Retina specialists review clinical trial data on the impact of anti-VEGF agents on diabetic retinopathy severity scores.

Joseph M. Coney, MD, provides an overview of the drug faricimab for treating diabetic macular edema.

Dr. Ehsan Rahimy describes the emerging treatment options for diabetic macular edema.

Dr Theodore Leng discusses what the future may hold for patients with diabetic macular edema.